Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.69 |
| ▸ | DPP4 | P27487 | 19/20 | 0.62 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.60 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.60 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6256625 | 1.00 | PREP (0.69) | PREPDPP4DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL15129998 | 0.98 | PREP (0.67) | PREPDPP4DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL4095441 | 0.98 | PREP (0.67) | PREPDPP4DPP8DPP9DPP7 | |
| Trifluoroacetic Acid SCHEMBL15129846 | 0.89 | DPP4 (0.59) | PREPDPP4DPP8DPP9DPP7 | |
| Trifluoroacetic Acid SCHEMBL15129845 | 0.89 | DPP4 (0.59) | PREPDPP4DPP8DPP9DPP7 | |
| Trifluoroacetic Acid SCHEMBL15129820 | 0.88 | DPP4 (0.58) | PREPDPP4DPP8DPP9DPP7 | |
| SCHEMBL10208867 | 0.84 | PREP (0.66) | PREPDPP4DPP8DPP9 | |
| SCHEMBL1677554 | 0.84 | DPP4 (0.54) | PREPDPP4DPP8DPP9DPP7 | |
| SCHEMBL2418371 | 0.84 | DPP4 (0.54) | PREPDPP4DPP8DPP9DPP7 | |
| SCHEMBL13185671 | 0.84 | PREP (0.66) | PREPDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140057901-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2014-02-27 | — | — | US | claimed |
| EP-2298769-B1 | Xanthin derivatives, their production and utilisation as medicine | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-10-30 | — | — | EP | claimed |
| US-20130165428-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-06-27 | — | — | US | claimed |
| EP-1953162-B9 | Xanthin derivatives, their production and utilisation as medicine | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-10-31 | — | — | EP | claimed |
| US-20120252783-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA & CO. KG (DE) | 2012-10-04 | — | — | US | claimed |
| US-20120252782-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG (DE) | 2012-10-04 | — | — | US | claimed |
| EP-1953162-B1 | Xanthin derivatives, their production and utilisation as medicine | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-06-20 | — | — | EP | claimed |
| US-20120040982-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA & CO. KG (DE) | 2012-02-16 | — | — | US | claimed |
| US-20110144083-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-16 | — | — | US | claimed |
| US-20110144095-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA & CO. KG (DE) | 2011-06-16 | — | — | US | claimed |
| US-20060205711-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-09-14 | — | — | US | claimed |
| US-20050014703-A1 | Cell differentiation, regeneration of epithelium pancreas cells into insulin producing beta-cells; administrering a peptidyl- peptidase activator | PROSIDION LIMITED (GB) | 2005-01-20 | — | — | US | claimed |
| US-20040087587-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | US | claimed |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-04-22 | — | — | US | claimed |
| EP-1296974-A2 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2003-04-02 | — | — | EP | claimed |
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-26 | — | — | US | claimed |
| US-20020193390-A1 | Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV | VILLHAUER EDWIN BERNARD (US) | 2002-12-19 | — | — | US | claimed |
| US-6432969-B1 | NON-INSULIN DEPENDENT DIABETES, OBESITY, ARTHRITIS, AND OSTEOPOROSIS TREATMENT | NOVARTIS AG (CH) | 2002-08-13 | — | — | US | claimed |
| WO-2001096295-A2 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2001-12-20 | — | — | WO | claimed |
| US-20010051646-A1 | Administering a dipeptidyl aminopeptidase effector which is selected from the group consisting of N-(N-substituted glycyl)2-cyanopyrrolidones, N-aminoacyl thiazolidines, N-aminoacyl pyrrolidines | PROSIDION LIMITED (GB) | 2001-12-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144083-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | DPP4, DPP3, DPP7 | PREP 14/4885DPP4 1/4885DPP8 5/4885 |
| US-20110144095-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | PREP 14/4885DPP4 1/4885DPP8 5/4885 |
| US-20040087587-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | PREP 30/4885DPP4 1/4885DPP8 5/4885 |
| US-20130165428-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | PREP 14/4885DPP4 1/4885DPP8 5/4885 |
| US-20120252783-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | PREP 14/4885DPP4 1/4885DPP8 5/4885 |
| US-20060205711-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | PREP 14/4885DPP4 1/4885DPP8 5/4885 |
| US-20120252782-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | DPP4, DPP3, DPP7 | PREP 14/4885DPP4 1/4885DPP8 5/4885 |
| US-20140057901-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | PREP 14/4885DPP4 1/4885DPP8 5/4885 |
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | PREP 30/4885DPP4 1/4885DPP8 5/4885 |
| US-20020193390-A1 | Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV | DPP4, DPP9, DPP7 | PREP 72/4885DPP4 1/4885DPP8 6/4885 |
| US-20120040982-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | PREP 14/4885DPP4 1/4885DPP8 5/4885 |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | DPP4, DPP3, DPP7 | PREP 18/4885DPP4 1/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.